NASDAQ:WVE WAVE Life Sciences (WVE) Stock Price, News & Analysis $8.34 +0.33 (+4.12%) Closing price 04:00 PM EasternExtended Trading$8.44 +0.10 (+1.20%) As of 05:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About WAVE Life Sciences Stock (NASDAQ:WVE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get WAVE Life Sciences alerts:Sign Up Key Stats Today's Range$7.97▼$8.7350-Day Range$5.94▼$8.3452-Week Range$5.04▼$16.74Volume2.46 million shsAverage Volume1.33 million shsMarket Capitalization$1.30 billionP/E RatioN/ADividend YieldN/APrice Target$20.15Consensus RatingModerate Buy Company Overview WAVE Life Sciences Corporation is a clinical-stage biotechnology company dedicated to the development of stereopure oligonucleotide therapies that address underlying genetic drivers of disease. The company leverages a proprietary platform to design and manufacture single-isomer oligonucleotides with enhanced potency, specificity and durability. Its research and development efforts are focused on a range of neuromuscular, neurodegenerative and metabolic disorders with significant unmet medical need. WAVE’s Precision Oligo™ chemistry platform enables the production of oligonucleotides with defined three-dimensional structures, which the company believes can improve tissue distribution and therapeutic indices relative to conventional oligos. Key programs in clinical development include treatments for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), with additional preclinical efforts targeting Huntington’s disease, acute hepatic porphyria and other rare genetic conditions. WAVE has also entered strategic collaborations with major biopharmaceutical partners to accelerate discovery and development of oligonucleotide-based oncology and metabolic disease programs. Founded in 2014 and headquartered in Cambridge, Massachusetts, WAVE Life Sciences operates complementary research facilities in the United Kingdom and maintains partnerships in Asia and Europe to support global development. The company’s leadership team combines expertise in oligonucleotide chemistry, clinical development and manufacturing scale-up, positioning WAVE to advance its pipeline through late-stage trials and regulatory filings. With a mission to translate cutting-edge oligonucleotide science into transformative therapies, WAVE continues to expand its platform capabilities and foster collaborations that broaden its therapeutic reach.AI Generated. May Contain Errors. Read More WAVE Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks92nd Percentile Overall ScoreWVE MarketRank™: WAVE Life Sciences scored higher than 92% of companies evaluated by MarketBeat, and ranked 94th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingWAVE Life Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 12 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageWAVE Life Sciences has only been the subject of 4 research reports in the past 90 days.Read more about WAVE Life Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for WAVE Life Sciences are expected to grow in the coming year, from ($1.14) to ($1.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of WAVE Life Sciences is -9.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of WAVE Life Sciences is -9.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioWAVE Life Sciences has a P/B Ratio of 6.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about WAVE Life Sciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted73.25% of the float of WAVE Life Sciences has been sold short.Short Interest Ratio / Days to CoverWAVE Life Sciences has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in WAVE Life Sciences has recently increased by 482.19%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldWAVE Life Sciences does not currently pay a dividend.Dividend GrowthWAVE Life Sciences does not have a long track record of dividend growth. Sustainability and ESG4.8 / 5Environmental Score-0.58 Percentage of Shares Shorted73.25% of the float of WAVE Life Sciences has been sold short.Short Interest Ratio / Days to CoverWAVE Life Sciences has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in WAVE Life Sciences has recently increased by 482.19%, indicating that investor sentiment is decreasing significantly. News and Social Media3.1 / 5News Sentiment0.65 News SentimentWAVE Life Sciences has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.96 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for WAVE Life Sciences this week, compared to 6 articles on an average week.Search Interest3 people have searched for WVE on MarketBeat in the last 30 days. MarketBeat Follows3 people have added WAVE Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, WAVE Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $208,500.00 in company stock.Percentage Held by Insiders23.98% of the stock of WAVE Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.73% of the stock of WAVE Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about WAVE Life Sciences' insider trading history. Receive WVE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for WAVE Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address WVE Stock News HeadlinesBreaking Down WAVE Life Sciences: 4 Analysts Share Their ViewsJuly 16 at 6:40 PM | benzinga.comCitigroup Initiates Coverage of Wave Life Sciences (WVE) with Buy RecommendationJuly 16 at 6:40 PM | msn.comTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada the 51st state because he’s desperate for critical minerals… They think his involvement in Ukraine is just another resource grab… They think his tariffs will wreck the economy… But they’re all missing the bigger picture.July 18 at 2:00 AM | Porter & Company (Ad)Wave Life Sciences Unveils Promising Preclinical Data for Obesity Treatment WVE-007 at ADA Scientific SessionsJuly 15 at 12:03 AM | msn.comLeerink Partners Reiterates a Buy Rating on Wave Life Sciences (WVE), Keeps the PT at $24July 11, 2025 | msn.comNASDAQ:WVE Financials | Wave Life Sciences Ltd - Investing.comJuly 11, 2025 | investing.comBrokerages Set WAVE Life Sciences Ltd. (NASDAQ:WVE) PT at $20.50July 9, 2025 | americanbankingnews.comWAVE Life Sciences Ltd. Company & People | WVE | Barron'sJuly 7, 2025 | barrons.comSee More Headlines WVE Stock Analysis - Frequently Asked Questions How have WVE shares performed this year? WAVE Life Sciences' stock was trading at $12.37 at the start of the year. Since then, WVE shares have decreased by 32.6% and is now trading at $8.34. How were WAVE Life Sciences' earnings last quarter? WAVE Life Sciences Ltd. (NASDAQ:WVE) posted its quarterly earnings results on Thursday, May, 8th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.27) by $0.02. The firm had revenue of $9.18 million for the quarter, compared to analyst estimates of $11.65 million. Read the conference call transcript. How do I buy shares of WAVE Life Sciences? Shares of WVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of WAVE Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that WAVE Life Sciences investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Intel (INTC) and Netflix (NFLX). Company Calendar Last Earnings5/08/2025Today7/18/2025Next Earnings (Estimated)8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:WVE CIK1631574 Webwww.wavelifesciences.com Phone(656) 236-3388Fax617-949-2901Employees240Year FoundedN/APrice Target and Rating Average Price Target for WAVE Life Sciences$20.15 High Price Target$36.00 Low Price Target$10.00 Potential Upside/Downside+149.6%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($0.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$97.01 million Net MarginsN/A Pretax Margin-107.04% Return on Equity-86.49% Return on Assets-37.20% Debt Debt-to-Equity RatioN/A Current Ratio2.95 Quick Ratio2.95 Sales & Book Value Annual Sales$108.30 million Price / Sales11.60 Cash FlowN/A Price / Cash FlowN/A Book Value$1.37 per share Price / Book5.89Miscellaneous Outstanding Shares155,560,000Free Float118,259,000Market Cap$1.26 billion OptionableOptionable Beta-1.01 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:WVE) was last updated on 7/18/2025 by MarketBeat.com Staff From Our Partners[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | SponsoredWill I be blacklisted?Porter Stansberry says a financial force bigger than 9/11 or COVID is already ripping through America — and mo...Porter & Company | SponsoredWhen your faith is put to the test, what will you do?Former CIA advisor Jim Rickards believes President Trump has just unlocked what the Bible foretold — a $150 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding WAVE Life Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share WAVE Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.